Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APTIOM vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy
Moderate to severe pain where an opioid analgesic is appropriate
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Primarily glucuronidation via UGT2B7; also metabolized by CYP3A4, CYP2C19, and CYP1A2 to a lesser extent.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Approximately 90% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Volume of distribution is approximately 1.3 L/kg, suggesting extensive distribution into tissues.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Oral bioavailability is approximately 60% (range 53-68%).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Estimated creatinine clearance (Cr Cl) >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: reduce maintenance dose by 50%; Cr Cl <30 m L/min and not on hemodialysis: not recommended. Hemodialysis: 50 mg once daily with supplement of 25 mg after dialysis.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce maintenance dose by 50%; initiate at 50 mg once daily, titrate slowly. Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Children (≥4 years): Initial 1.5 mg/kg/day orally divided twice daily; titrate weekly by increments of 1.5 mg/kg/day to a maintenance of 3-6 mg/kg/day twice daily. Maximum: 400 mg twice daily.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
No specific dose adjustment based on age alone. Dose selection should be cautious, reflecting higher frequency of decreased renal/hepatic function and concomitant disease or drug therapy. Consider creatinine clearance and titrate slowly.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
None
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Suicidal behavior and ideation,Angioedema,Anaphylaxis,Dermatological reactions including Stevens-Johnson syndrome,Decreased serum sodium,Dizziness and gait disturbance,Hepatic injury
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Known hypersensitivity to eslicarbazepine acetate or any oxcarbazepine derivative
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Take with or without food. No specific food interactions reported.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of fetal antiepileptic drug syndrome (facial dysmorphism, growth retardation, neurodevelopmental delay). Neonatal hemorrhage due to vitamin K deficiency may occur.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Excreted in human milk. Milk-to-plasma ratio not established. Potential for serious adverse reactions in nursing infants (sedation, poor suckling). Use only if benefit outweighs risk; consider alternative anticonvulsants.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Pregnancy increases clearance of eslicarbazepine acetate by approximately 30-40% in the second and third trimesters. Dose may require up to 50-100% increase from baseline to maintain therapeutic levels. Postpartum clearance returns rapidly; reduce dose promptly to avoid toxicity.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
APTIOM (eslicarbazepine acetate) is a once-daily antiepileptic drug for partial-onset seizures. Monitor serum sodium, especially in elderly or those on concomitant hyponatremia-inducing drugs. Titrate to maintenance dose over 2 weeks. Avoid abrupt discontinuation. Contraindicated in second- or third-degree AV block.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Take exactly as prescribed once daily; do not crush or chew tablets.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy.,Do not stop abruptly; withdrawal may increase seizure frequency.,Avoid driving until effects on dizziness or somnolence are known.,Notify doctor if pregnant, planning pregnancy, or breastfeeding.,Use effective contraception as APTIOM may reduce hormonal contraceptive efficacy.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
No interactions on record
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APTIOM vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
APTIOM is a Anticonvulsant that works by Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APTIOM and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APTIOM is: Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APTIOM and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APTIOM is classified as Category C. Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and thir. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.